Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players√Ę‚ā¨‚ĄĘ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst

ADHD Therapeutics Market Research Report Information by Drug Type (Stimulants and Non-Stimulants), Age Group (Pediatric & Adolescent and Adults), End-User (Specialty Clinics, Hospitals & Clinics, and others) and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2032


ID: MRFR/Pharma/1044-HCR | 80 Pages | Author: Kinjoll Dey| April 2024

ADHD Therapeutics Market Overview


The adhd therapeutics market is anticipated to reach USD 19.8 Billion by 2032 at 7.9% CAGR during the forecast period 2023-2032. According to the latest research report, it is anticipated that the ADHD Therapeutics Market would develop at a substantial rate throughout the projected period. Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) have persistent patterns of inattention and hyperactivity-impulsivity that interfere with their ability to function or grow normally.


Aspects such as the growing incidence of attention deficit hyperactivity disorder (ADHD), the increasing usage of chemical additives in children's food, and more awareness about ADHD are projected to drive the market's development. Comorbid disorders in children contribute to attention deficit hyperactivity disorder (ADHD) underdiagnosis. During the projected period, this factor will have a negative impact on market growth. Furthermore, the restricted accessibility of non-stimulant medications is projected to have a negative impact on the industry.


This report contains all the information on the global ADHD Therapeutics Market analysis and its strengths. The report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other essential factors. And a detailed analysis of the ADHD Therapeutics Market forecast for 2030 is also included in the report.


Covid 19 Analysis


With the COVID-19 outbreak and physical distancing tactics, people with hyperactivity disorder (ADHD) face an incredibly challenging moment. Individuals with ADHD may have an increase in behavioural issues as a consequence of these interventions. As a result of this, the ADHD market value, medications is expected to rise significantly.


As a consequence of panic purchases by customers, crucial drugs have run out of supply, necessitating the deployment of a fresh batch by players. ADHD medications are no exception.


The expansion of the market is anticipated to be fueled by factors such as the rising prevalence of attention deficit hyperactivity disorder (ADHD), the rising prevalence of chemical additives in children's food, and greater awareness of ADHD. Children with ADHD are underdiagnosed in part because of the prevalence of co-occurring illnesses. This aspect will restrain market expansion during the forecast time frame. A further detrimental influence on the market is anticipated from the limited availability of non-stimulant drugs.


Extensive studies evaluating the safety and efficacy of drugs for people with attention deficit hyperactivity disorder are expected to fuel market expansion in the near future. When these research yield positive results, it opens up new avenues for business. Opportunities for growth may arise if market leaders increase their product promotion activities.


As more people (including patients, doctors, and other healthcare professionals) learn about attention deficit hyperactivity disorder, the market for therapeutics to treat it is expected to expand. These possibilities are expected to increase the demand for ADHD treatment solutions. The advertising and partnership agreements for the product will have a greater impact because of the increased size of the sales force.


May 2023: Researchers found that Akili's EndeavorRx, a video game-based treatment for ADHD, improved adults' sustained and selective attention at a rate nearly seven times that of the original, younger test group, according to the study's primary outcomes, which were published in May 2023. The number of adults diagnosed with attention deficit hyperactivity disorder (ADHD) has been rising in recent years, and officials have speculated that the game-based treatment could fill a void in the market for non-drug ADHD remedies.


ADHD Therapeutics Market Trends  


Drivers


As more people become aware of attention deficit hyperactivity disorder (ADHD) among patients, doctors, and other medical practitioners, the need for effective treatment is expected to rise, resulting in ADHD Therapeutics market growth.


Opportunities


Due to the existence of solid wholesalers and distribution channels in Germany, the market of ADHD therapeutics in Europe is expected to be dominated by the country. Opportunities for ADHD treatment systems in such areas are expected to expand the market. A larger sales team will also increase the product's marketing and partnership agreements' reach throughout these two areas.


Restraints


Adverse reactions and contraindications to ADHD medications are restricting the number of scripts that may be issued, which is predicted to have an impact on income.


Challenges


Among the most significant challenges facing the worldwide ADHD therapeutics market outlook are the high cost of ADHD drugs, inappropriate funding procedures, and side effects associated with ADHD medications such as sleeplessness, anorexia, nausea, migraines, and mood abnormalities.


Cumulative Growth Analysis


According to data published by the Centers for Disease Control and Prevention (CDC), roughly 6.1 million people, which is 9.4 per cent in the United States, were identified with attention deficit hyperactivity disorder ADHD in 2016. This contains 388,000 kids aged 2‚Äď5 years, 4 million kids aged 6‚Äď11 years, and 3 million kids aged 12‚Äď17 years. In addition, males are more likely than females to be involved in Developing, according to the American Academy of Pediatrics.


The frequency of attention-deficit hyperactivity disorder (ADHD) is increasing at an astonishing rate, which is projected to drive sales increase in the worldwide market of ADHD therapeutics, which currently lacks a therapy for the illness in question.


ADHD Therapeutics Market Segmentation


According to the reports, The market of ADHD therapeutics has been divided based on the Drug type, age range, end-user, and geographic area in which it operates. by drug type The market of ADHD therapeutics has been segmented into two groups stimulants and non-stimulants. The stimulants sector is further subdivided into the following categories: amphetamine, dexmethylphenidate, methylphenidate, lisdexamfetamine, dextroamphetamine, and other stimulants. Because of physicians' strong preference for medicine, the lisdexamfetamine sub-segment is likely to be the most significant section in the market. Non-stimulants are further subdivided into atomoxetine, guanfacine, bupropion, and clonidine, which are all antidepressants.


by age group the market of ADHD therapeutics market has been segmented into paediatrics, adolescents and adults. Depending on the end-user, the market for ADHD therapies has been categorized into hospitals & clinics, specialist clinics, and other organizations.


June 2023: Cingulate's CTx-1301 (dexmethylphenidate) trial to treat adult attention-deficit/hyperactivity disorder (ADHD) was completed in June 2023. The start and duration of CTx-1301 were assessed in an adult laboratory classroom (ALC) setting as part of a parallel effectiveness and safety, placebo-controlled, double-blind, dose-optimized, single-centre, randomized investigation. In addition, a dose-optimization onset and duration trial in pediatric patients, as well as a Phase III fixed-dose research in children and adolescents, are scheduled to begin in the third quarter of 2023.


June 2023: Cingulate's CTx-1301 (dexmethylphenidate) trial to treat adult attention-deficit/hyperactivity disorder (ADHD) was completed in June 2023. The start and duration of CTx-1301 were assessed in an adult laboratory classroom (ALC) setting as part of a parallel effectiveness and safety, placebo-controlled, double-blind, dose-optimized, single-centre, randomized investigation. In addition, a dose-optimization onset and duration trial in pediatric patients, as well as a Phase III fixed-dose research in children and adolescents, are scheduled to begin in the third quarter of 2023.


Regional Analysis


According to the reports, The ADHD Therapeutics Market is bifurcated into the Americas, Europe, Asia-Pacific, and the Middle East & Africa in terms of geographic location. It is expected that the Americas would lead the market for ADHD treatments due to the region's well-developed healthcare system, increased incidence of ADHD and early authorization of medicines. A maximum of 6.1 million American children was diagnosed with ADHD between 2012 and 2016.


As a result of government assistance and improved healthcare r & d, Europe is believed to maintain second place in the ADHD therapeutics market share. This region's ADHD treatment market includes all of Asia-countries Pacific's including but not limited to: India, China, Australia, Japan, South Korea, and the rest. As the incidence of ADHD rises and healthcare costs rise, Asia-Pacific is predicted to be a high-speed area in the global ADHD market. Children and teenagers in China have an ADHD prevalence of 6.26 per cent, according to a report released by the National Center for Biotechnology Information in January 2017.


The Middle East and Africa are predicted to have the smallest market share during the projected period. The medical system in this area is projected to fuel the market's development.


Competitive landscape


Manufacturers are targeting both youngsters with ADHD and adults with the disorder. To make them more appealing to children, certain medications are flavoured to make them more palatable, while for grownups, the goal is to provide a long-lasting impact so that they don't have to take as many tablets each day.


Major Key Players



  • Advanz Pharmaceutical (Canada)

  • Eli Lilly and Company (US)

  • Highland Therapeutics Inc. (Canada)

  • Janssen Pharmaceuticals, Inc. (Belgium)

  • NEOS Therapeutics, Inc. (US)

  • Pfizer Inc. (US)

  • Novartis AG (Switzerland)

  • Noven Pharmaceuticals, Inc. (US)

  • Shire (US)

  • Teva Pharmaceutical Industries Ltd. (Israel)

  • Impax Laboratories, LLC (US)

  • GlaxoSmithKline plc (UK)

  • Purdue Pharma L.P. (US)


Report Overview


The following report comprises of ‚Äď



  • Market overview¬†

  • Covid 19 Analysis

  • Market Dynamic

  • Drivers

  • Opportunities

  • Restraints¬†

  • Challenges

  • Cumulative Growth Analysis

  • Value Chain Analysis

  • Segmentation Overview¬†

  • By Application¬†

  • By End-Users

  • Regional Analysis

  • Competitive landscape


Recent Developments



  • Tris Pharma Inc. completed the acquisition of NextWave Pharmaceuticals in September 2018, therefore expanding its ADHD product range.


ADHD Therapeutics Drug Type Outlook



  • Stimulants

    • Amphetamine

    • Methylphenidate

    • Dextroamphetamine

    • Dexmethylphenidate

    • Lisdexamfetamine

    • Other



  • Non-StimulantsAtomoxetine

    • Bupropion

    • Guanfacine

    • Clonidine




ADHD Therapeutics Age Group Outlook



  • Pediatric and Adolescents

  • Adults


ADHD Therapeutics End User Outlook



  • Specialty Clinics

  • Hospital Pharmacies

  • Retail Pharmacies

  • Others


ADHD Therapeutics Region Outlook




  • Americas

    • North America

      • US

      • Canada

      • Latin America






  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe




  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • Middle East & Africa

    • Middle East

    • Africa



Report Attribute/Metric Details
  Market Size   USD 19.8 Billion
  CAGR   7.9%
  Base Year   2022
  Forecast Period   2023-2032
  Historical Data   2021
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Type, Age Group and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Advanz Pharmaceutical (Canada), Eli Lilly and Company (US), Highland Therapeutics Inc. (Canada), Janssen Pharmaceuticals, Inc. (Belgium), NEOS Therapeutics, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Noven Pharmaceuticals, Inc. (US), Shire (US), Teva Pharmaceutical Industries Ltd. (Israel), Impax Laboratories, LLC (US), GlaxoSmithKline plc (UK) and Purdue Pharma L.P. (US)
  Key Market Opportunities   The existence of comorbid conditions in children leads to underdiagnoses of ADHD
  Key Market Drivers ·  rising prevalence of ADHD ·  rising use of additives & preservatives in children’s diet ·  increasing awareness regarding ADHD


Frequently Asked Questions (FAQ) :

The ADHD therapeutics market is expected to exhibit a CAGR of 7.9% from 2022-2032.

The ADHD therapeutics market stood at 19.8 Billion in 2032.

Awareness of ADHD, inclusion of additives in the diets of children, and alarming cases of ADHD are major drivers of the ADHD therapeutics market.

Limited production on non-stimulation drugs can hamper the ADHD therapeutics market.

The Americas can dominate the ADHD therapeutics market till 2025 due to early approvals of therapeutics in the region.

Janssen Pharmaceuticals, Inc., NEOS Therapeutics, Inc., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline plc, Noven Pharmaceuticals, Inc., Purdue Pharma L.P., Highland Therapeutics Inc., Impax Laboratories, LLC, Advanz Pharmaceutical, and Shire are major players of the ADHD therapeutics market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Request Free Sample
Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Ask for Customization